Feverfew
A flowering herb referenced in traditional herbal literature and modern supplement discussions.
Overview
Feverfew (Tanacetum parthenium) is a perennial flowering herb in the Asteraceae (daisy) family, native to southeastern Europe and now widely naturalized across temperate regions. It is one of a relatively small number of botanical ingredients whose traditional use is strongly associated with a specific symptom category — in this case, Headache — a connection that has persisted from medieval European herbalism into modern supplement marketing. Feverfew occupies a distinctive position in the botanical supplement landscape: it has been the subject of more focused clinical research than many traditional herbs, yet the evidence base remains inconclusive and product standardization challenges have complicated the interpretation of published findings. This page is educational and does not recommend use for any condition.
What it is
Feverfew (Tanacetum parthenium, formerly classified as Chrysanthemum parthenium) is a bushy, aromatic herb with small daisy-like flowers and deeply lobed leaves. The leaves are the plant part most commonly used in supplement products, though some formulations use aerial parts more broadly. The compound most frequently discussed in both phytochemistry and supplement literature is parthenolide — a sesquiterpene lactone found primarily in the leaf glandular trichomes — which has been the focus of most mechanistic and standardization discussions surrounding feverfew.
Consumer products include dried leaf capsules, freeze-dried leaf preparations, liquid extracts, and standardized extract capsules. Parthenolide content varies substantially across products — by cultivar, growing conditions, harvest timing, processing method, and storage — and this variability has been a persistent issue in both research and quality discussions. Some products are standardized to a specific parthenolide content, while others use whole-leaf or unstandardized preparations. The term "feverfew" on a label does not indicate a uniform composition, and the distinction between standardized and unstandardized products is a recurring consideration in the literature.
Traditional use (educational)
Feverfew has a documented traditional use history in European herbalism dating back at least to the medieval period, with the common name itself reflecting an older English reference to its association with fever-related narratives (from the Latin febrifugia). The 17th-century English herbalist Nicholas Culpeper and other prominent European herbalists referenced feverfew in their texts, though the specific traditional contexts and attributed uses varied across time periods and regional traditions. In British folk herbalism, the practice of chewing fresh feverfew leaves became a particularly well-known folk narrative during the 20th century — one that drew renewed popular and scientific attention in the 1970s and 1980s.
The traditional association between feverfew and head discomfort narratives is the most persistent and culturally specific of its folk references, distinguishing it from many other traditional herbs whose traditional use records are broader and less focused. This narrow traditional association has shaped how feverfew is positioned in the modern supplement market and has driven much of the clinical research agenda. As with all traditional references, these historical patterns reflect cultural practice and observational narrative rather than controlled evidence.
What research says
Feverfew has been the subject of a modest but notable body of clinical research, primarily conducted between the 1980s and 2000s, with most studies examining dried leaf or parthenolide-standardized preparations in the context of head discomfort-related outcomes. The results of these trials have been mixed — some early studies reported findings of interest, while subsequent larger or more rigorously designed trials have produced less consistent results. The heterogeneity of products studied (differing in parthenolide content, leaf preparation method, and formulation) is a widely acknowledged limitation that makes cross-study comparison difficult.
Parthenolide has been the focus of in vitro and animal model research exploring its interactions with various cellular pathways, including those involved in inflammatory signaling and platelet aggregation. These mechanistic investigations are preliminary and laboratory-based — the relevance of isolated compound studies to whole-leaf preparations consumed by humans is an open question. Systematic reviews and major health reference sources — including NCCIH — generally characterize the evidence base for feverfew as inconclusive, noting that while the ingredient has a more developed research history than many botanicals, the current evidence is insufficient to confirm specific outcomes. The gap between feverfew's relatively focused traditional reputation and the ambiguity of its clinical evidence base is a defining feature of the contemporary discussion.
Safety & interactions
Feverfew is discussed in safety literature as generally well-tolerated by most individuals in short-term use, though several side effects and considerations are documented. Mouth ulceration and oral irritation are among the more frequently reported side effects — particularly associated with chewing fresh leaves, the traditional folk method — and gastrointestinal symptoms are noted in some clinical trial records. A phenomenon sometimes referred to as "post-feverfew syndrome" — involving rebound symptoms after discontinuation of long-term use — appears in some educational references, though this observation comes from limited and largely anecdotal reports.
Pharmacological reference material notes theoretical interaction potential between feverfew and anticoagulant or antiplatelet medications, based on in vitro observations of parthenolide's effects on platelet aggregation pathways. The clinical significance of this theoretical interaction at typical supplement use levels is not well-established. Allergic reactions are documented in some individuals, particularly those with existing sensitivities to plants in the Asteraceae family (which includes ragweed, chamomile, and chrysanthemums). Cross-reactivity with these related plants is noted in allergy-focused literature.
Who should be cautious
Pregnant individuals are consistently identified in educational literature as a population where feverfew warrants particular awareness — the plant has a historical association with uterine stimulant narratives in folk herbalism, and safety data in pregnancy is limited. Individuals with known allergies to Asteraceae-family plants encounter standard cross-reactivity cautionary notes. People taking anticoagulant or antiplatelet medications are identified in pharmacological references as a population warranting awareness, given the theoretical interaction considerations related to platelet activity.
Individuals experiencing persistent or severe Headache patterns are consistently noted in conventional health sources as candidates for professional evaluation, as symptom characterization and underlying cause assessment are relevant considerations that fall outside the scope of supplement use. Professional consultation is a consistent theme across conventional health sources for anyone with complex health considerations or medication regimens.
Quality & sourcing considerations
Parthenolide content is the most frequently discussed quality variable for feverfew products, and it is also one of the most problematic — published analyses have documented wide variability in actual parthenolide content across commercial products, with some products containing little to no detectable parthenolide despite label claims. This inconsistency is attributed to cultivar differences, harvest timing, processing method (heat exposure can degrade parthenolide), and storage conditions, and it has been a recognized issue in both quality and research discussions for decades.
Products standardized to a declared parthenolide content offer more compositional specificity than unstandardized whole-leaf preparations, though the accuracy of standardization claims varies across manufacturers. Third-party testing for identity, parthenolide content, and contaminants is frequently cited as a quality indicator in educational sourcing discussions. The plant part used (leaves versus aerial parts versus whole plant) and the preservation method (freeze-dried versus air-dried versus extracted) are additional quality variables noted in the literature. Labeling specificity regarding these factors varies considerably across the consumer market.
FAQs
Do feverfew products vary?
Yes, substantially. Parthenolide content — the compound most commonly cited in feverfew supplement discussions — varies widely across commercial products due to differences in cultivar, growing conditions, harvest timing, processing method, and storage. Some products are standardized to a specific parthenolide percentage, while others are whole-leaf or unstandardized preparations. Published market analyses have documented significant discrepancies between label claims and actual parthenolide content across brands.
Is feverfew always taken as a supplement?
No. Feverfew has a traditional history of use as a fresh or dried herb — the folk practice of chewing fresh leaves is one of the more well-known traditional narratives — and dried-leaf tea preparations also appear in traditional references. In the modern market, capsules and standardized extracts are the most common supplement formats, but the ingredient is encountered across a range of product types with different composition and concentration profiles.